BiotechTube
Home/Lutris Pharma/Colleen Johnson, M.S, DABT
CJ

Colleen Johnson, M.S, DABT

Director, Pre‑Clinical Development

Lutris Pharma

Therapeutic Areas

Oncology

Lutris Pharma Pipeline

DrugIndicationPhase
LUT014EGFR inhibitor‑induced acneiform lesions in metastatic colorectal cancerPhase 2

Leadership Team at Lutris Pharma

SR
Sumant Ramachandra, M.D., Ph.D., MBA
Chief Executive Officer and Board Director
JP
John Paul Waymack, M.D., Sc.D.
Director, Regulatory Affairs
LM
Laura Millichamp, Ph.D.
Director, Chemistry Manufacturing Control
View full Lutris Pharma profile